Dare to Commercialize: Damien Perriman’s eXoZymes Playbook

Written By Lizette Couto

Damien Perriman, Chief Commercial Officer of eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules. Damien explains why the team spun NCTX out as a separate commercial vehicle, what it means to successfully transfer a process to a partner manufacturer (including a milestone Cayman validation), and why NCT (n-trans-caffeoyl tyramine), a trace compound found in peppercorns and hemp seed husks, has drawn so much attention as the only known agonist of HNF4A, a metabolic “switch” tied to mitochondrial function.

The conversation also covers the logic behind launching first in supplements, how to build credibility in a crowded category through safety and product consistency, how regulatory timelines shape strategy, and why industrial biotech needs to move from platform-first stories to molecule-led business cases that match real market demand.

Chapters:

  • (00:00:00) Welcome, introductions, and why tech transfer matters

  • (00:02:10) Why eXoZymes spun out NCTX to commercialize faster

  • (00:03:30) Cayman scale-up milestone: 99% conversion and 99.6% purity

  • (00:05:20) What the Cayman validation proves for product delivery and partners

  • (00:08:10) Why launch NCT in supplements first, and what GRAS enables

  • (00:10:00) Building credibility in supplements: safety, purity, and consistency

  • (00:12:05) What HNF4A is, and why NCT is the only known agonist

  • (00:14:30) What’s next: more human use studies, dose regimens, and GLP-1 adjacencies

  • (00:16:00) NCT vs GLP-1s: “metabolic restoration” and where it might fit

  • (00:18:10) “Natural” vs safe and effective: what really matters

  • (00:21:00) Examples of trace natural molecules scaled for human use

  • (00:22:30) GRAS + FDA timelines: how they’re navigating regulatory reality

  • (00:26:00) The Molecule Manifesto: why industrial biotech needs molecule-led business cases

  • (00:31:00) How eXoZymes chooses what to work on (idea management system)

  • (00:33:00) Vision: what success looks like in 5–10 years

  • (00:35:00) Quickfire: NCT in ice cream, NCT as “WALL-E,” and other rapid takes

  • (00:38:10) What people misunderstand about cell-free biomanufacturing

  • (00:40:00) Wrap-up + post-episode reflection

Episode Links:

Lizette Couto
Previous

Dye Another Day (REPLAY): The New Way to Color Textiles with Colorifix's Orr Yarkoni
Next

Seaweed Is the New Oil: Mari Granström Builds Origin by Ocean